相关实验视频

Updated: Jun 26, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

针对非小细胞肺癌中的KRASG12D突变:分子机制和治疗潜力

Yining Tang¹, Xi Pu¹, Xiao Yuan¹

¹Department of Radiation Oncology, Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, 212000, Jiangsu, China.

Cancer gene therapy

|May 11, 2024

概括

非小细胞肺癌 (NSCLC) 是一个主要的全球健康问题. 虽然针对KRASG12C突变的向疗法显示出希望,但开发更常见的KRASG12D亚型的有效治疗仍然是一个重大挑战.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

非小细胞肺癌 (NSCLC) 在全球呈现高发病率和死亡率,大多数诊断发生在晚期.
基尔斯大鼠肉瘤 (KRAS) 是人类癌症中最常见的致癌驱动突变,在NSCLC中尤其普遍.
尽管针对NSCLC的向疗法和免疫检查点抑制剂的进展,但向KRAS仍然具有挑战性,目前正在研究其作用和治疗策略.

研究的目的:

审查目前对NSCLC中KRAS突变的理解.
强调开发针对KRAS突变NSCLC的向疗法的挑战和进展,重点关注KRASG12C和KRASG12D亚型.
确定未满足的需求和未来的研究方向,以治疗KRAS突变NSCLC.

主要方法:

关于NSCLC中瘤性驱动因素变化的文献综述.
分析当前的向治疗和免疫检查点抑制剂的进展.
检查KRASG12C和KRASG12D向药物的研究进展情况.

主要成果:

在开发针对NSCLC的KRASG12C突变亚型的向药物方面取得了重大进展.
对更常见的KRASG12D亚型的向药物的研究正在滞后,目前还没有批准的治疗方法.
关键未回答的问题包括耐药机制,最佳组合策略,以及KRASG12D抑制剂在晚期NSCLC中的疗效.

结论:

针对NSCLC中的KRAS突变是研究的一个活跃领域,治疗策略正在不断发展.
克拉斯格12C亚型最近在治疗方面取得了进展,而克拉斯格12D亚型需要进一步的研究和药物开发.
未来的研究应该专注于克服耐药性,探索组合疗法,并确定KRASG12D抑制剂对晚期NSCLC患者的临床疗效.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...